Send me a link:

*Text messaging rates may apply.

 Dow Down0.12% Nasdaq Up0.46%

XTL Biopharmaceuticals Ltd. (XTLB)

3.25 Down 0.04(1.19%) 11:37AM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
XTL Biopharmaceuticals Ltd.
Building G
Herzliya Business Park
Herzliya, 46140
Israel - Map
Phone: 972 9 955 7080
Fax: 972 9 951 9727

Index Membership:N/A
Full Time Employees:12

Business Summary 

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. The company’s lead drug candidate is hCDR1, a Phase II clinical trial product for the treatment of systemic lupus erythematosus related autoimmune process; and recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma patients, as well as for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. Its rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases with focus on schizophrenia. It has a licensing agreement with Yeda Research and Development Company for the development of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is based in Herzliya, Israel.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on XTL Biopharmaceuticals Ltd.

Key Executives 
Mr. Joshua Levine , 49
Chief Exec. Officer and Director
Mr. David Kestenbaum , 49
Chief Financial Officer
Mr. Ronen Kantor Adv ,
Company Sec.
Prof. Moshe Mittelman , 61
Medical Director
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders